Quanpeng Li

Prof. Quanpeng Li

The People’s Hospital of Kizilsu Kirghiz Autonomous Prefecture

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2018 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
NWNi Wang
Ni Wang
YYYang Yu
Yang Yu
BXBoming Xu
Boming Xu
MZMingjiong Zhang
Mingjiong Zhang
QLQuanpeng Li
Quanpeng Li
LMLin Miao
Lin Miao
Long non‑coding RNAs (lncRNAs) have been classically defined as regulatory RNA members >200 nucleotides in length, without detectable open‑reading frames to encode proteins. Previous studies have demonstrated that lncRNAs serve critical roles in multiple cancer types. Colon cancer‑associated transcript 1 (CCAT1), a novel cancer‑associated lncRNA, is significantly overexpressed in a number of malignancies. Functionally, as an oncogenic lncRNA, CCAT1 is involved in proliferation, migration, cell cycle progression, apoptosis, chemoresistance and other biological processes of cancer cells through complex regulation mechanisms in the cytoplasm or nucleus. In clinical applications, CCAT1 is additionally positively associated with histological differentiation, tumour node metastasis stage, vascular invasion, overall survival and recurrence‑free survival, which demonstrates its important role as a diagnostic and prognostic marker in cancer. The present review summarises the current research progress of the oncogenic potential and clinical uses of CCAT1 in various human cancer types.

21 May 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
LTLingyu Tang
Lingyu Tang
YWYuting Wang
Yuting Wang
HWHuishan Wang
Huishan Wang
BXBoming Xu
Boming Xu
HJHao Ji
Hao Ji
LMLin Miao
Lin Miao
Cholangiocarcinoma (CCA) is a malignant tumor originating from bile duct epithelium and its incidence is increasing year by year. In recent years, long noncoding RNAs (lncRNAs) have been found to play an important role in the occurrence and progression of malignant tumors. In the present study, for the first time, abnormal expression of lnc‐RNA component of mitochondrial RNA processing endoribonuclease (RMRP) and its possible role in CCA were found. We explored the effects of RMRP on various behaviors of CCA cells in vitro and in vivo. In addition, by second‐generation sequencing, we explored the microRNA expression profiles that RMRP may affect in the HCCC‐9810 cell line. We also validated and explored the role of microRNA‐217 (miR‐217) with high differential expression by in vitro experiments. Our findings indicated that RMRP can play a part in promoting cancer by regulating the expression of miR‐217. RMRP is involved in the progression of CCA and can be a novel indicator of poor prognosis in patients with CCA.

25 June 2021 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
YWYuting Wang
Yuting Wang
WZWen Zhang
Wen Zhang
LCLin Chen
Lin Chen
WCWei Chen
Wei Chen
SXShufen Xu
Shufen Xu
LMLin Miao
Lin Miao

11 July 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HZHanlong Zhu
Hanlong Zhu
SZSi Zhao
Si Zhao
RJRuonan Jiao
Ruonan Jiao
HWHuishan Wang
Huishan Wang
RTRuiyi Tang
Ruiyi Tang
LMLin Miao
Lin Miao
Background: It has been widely reported that the expression levels of SNHG20 are elevated in diverse types of cancers, indicating that SNHG20 may participate in cancer initiation and development. Besides, accumulating evidence reveals that SNHG20 overexpression is also connected with poor clinical outcomes among cancer patients. Herein, we carry out a systematic meta-analysis to further determine the prognostic and clinical significance of SNHG20 expression in various human cancers. Methods: Qualifying publications were selected by searching for keywords in PubMed, Embase, Web of Science and Cochrane Library databases, up to September 1, 2019. Pooled hazard ratio (HR) or odds ratio (OR) with corresponding 95% confidence interval (CI) was computed to estimate the strength of association between SNHG20 and survival of cancer patients or clinicopathology using Stata 14.0 software. Results: In total, 15 studies encompassing 1187 patients met the inclusion criteria were ultimately enrolled for analysis. According to the meta-analysis, patients with high SNHG20 expression were markedly linked to poorer overall survival (OS) (pooled HR = 2.47, 95% CI 2.05–2.98, P = 0.000) and disease-free survival/recurrence-free survival/progression-free survival (DFS/RFS/PFS) (pooled HR = 2.37, 95% CI 1.60–3.51, P = 0.000). Additionally, regarding clinicopathology of patients, enhanced SNHG20 was correlated with advanced tumour‐node‐metastasis (TNM) stage (OR = 2.80, 95% CI 2.00–3.93, P = 0.000), larger tumor size (OR = 3.08, 95% CI 2.11–4.51, P = 0.000), positive lymph nodes metastasis (OR = 2.99, 95% CI 2.08–4.31, P = 0.000), higher tumor stage (OR = 4.51, 95% CI 2.17–9.37, P = 0.000) and worse histological grade (OR = 1.95, 95% CI 1.44–2.63, P = 0.000), but not with gender, smoking status or distant metastasis. Conclusions: Up-regulated SNHG20 expression is ubiquitous in different kinds of cancers. Moreover, up-regulated SNHG20 expression is capable of serving as an innovative predictive factor of inferior clinical outcomes in cancer patients. Nevertheless, higher-quality multicenter studies are required to corroborate our results.

18 September 2019 in Preprints.org
Verified
Preprint
Open access
PDF file
Fatema TabakFatema Tabak
Fatema Tabak
HWHui-Shan Wang
Hui-Shan Wang
QLQuanpeng Li
Quanpeng Li
XGXianxiu Ge
Xianxiu Ge
FWFei Wang
Fei Wang
LMLin Miao
Lin Miao
Endoscopic retrograde cholangiopancreatography (ERCP) is a routinely used therapeutic procedure for the biliary and pancreatic diseases. Population aging may increase the typical indications of ERCP and come with more complexity and difficulties, especially in cannulation. This study aimed to evaluate the incidence, causes, and management of difficult biliary cannulation during ERCP in super-aged patients and the role of difficult cannulation as a risk factor for adverse events. A total of 614 patients, underwent ERCP, were prospectively studied as a cohort and divided into two groups based on their age. There were 146 patients aged 80 years or older in group A and 468 patients aged less than 80 years in group B. The primary outcome measures were the difficulty grade of papilla cannulation, clinical outcomes, and ERCP-related complications in the two groups. The adverse events were analyzed using logistic regression for patient age, co-morbidities, indications, and cannulation difficulty grade variables. There was no difference in the incidence of difficult cannulation between the two groups (32.9% vs. 34.4%, p=0.765) though, as expected, super-aged Group A had a higher prevalence of periampullary diverticulum (29.5% vs. 16.7%, p=0.001). The technical cannulation success rate was (96.6% vs. 96.8%, p= 0.54). All used cannulation techniques in the elderly group were efficient and safe. Logistic regression showed that age ≥80 was not associated with increased adverse events; however, difficult cannulation (adjusted odds ratio [AOR]=3.478; 95% confidence interval [CI]=1.877, 6.442; p<0.001) and CCI ≥2 (AOR=1.824; 95% CI=0.993, 3.349; p=0.045) were more likely to have adverse events. Age ≤65 (AOR=3.460; 95% CI=1.511, 7.922; p=0.003), female gender (AOR=2.362; 95% CI=1.089, 5.124; p=0.030), difficult cannulation (AOR=4.527; 95% CI=2.078, 9.860; p<0.001), and patients with cholangitis (AOR=3.261; 95% CI=1.204, 8.832; p=0.020) were strongly associated with increasing Post-ERCP Pancreatitis (PEP). Advanced age has not proved to be a risk factor of difficult cannulation, and secondary cannulation techniques can be safely and efficaciously utilized for this group. CCI ≥2 and difficult cannulation are associated with increased overall adverse events rate while age ≥80 factor is not.